Barry Kricsfeld
Internal Medicine · Council Bluffs, IANPI 1083668636
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,434 of the $12,834 with a category attached, or 81.3%. 30 manufacturers reported payments, led by AbbVie at 24.7% of the total. Reporting peaked in 2022 at $4,169 and has fallen 86.2% since, to $577 in 2025. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $74.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Medtronic$976
- AstraZeneca$842
- Gilead$815
- Johnson & Johnson$807
- Sanofi-aventis U.S. LLC$653
- plus $6K from 24 others
What the payments were for
- Speaking & faculty fees$2,40019%
- Food & beverage$10,43481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 11 | $3,174 |
| Medtronic(3 entities) | 9 | $976 |
| AstraZeneca | 12 | $842 |
| Gilead | 9 | $815 |
| Johnson & Johnson | 16 | $807 |
| Sanofi-aventis U.S. LLC | 7 | $653 |
| Amgen | 20 | $648 |
| E.r. Squibb & Sons, L.L.C. | 8 | $547 |
| GSK | 4 | $435 |
| Novo Nordisk | 7 | $414 |
| Pfizer | 11 | $334 |
| Bayer | 3 | $322 |
| Boehringer Ingelheim | 5 | $296 |
| Esperion Therapeutics, Inc. | 4 | $280 |
| Avanir Pharmaceuticals, Inc. | 3 | $268 |
| Paratek Pharmaceuticals, Inc. | 2 | $252 |
| Axsome Therapeutics, Inc. | 2 | $240 |
| Sunovion Pharmaceuticals Inc. | 8 | $229 |
| Mylan Specialty L.p. | 3 | $201 |
| Biohaven Pharmaceuticals, Inc. | 2 | $201 |
| Lilly USA, LLC | 7 | $191 |
| Amarin Pharma, Inc. | 4 | $168 |
| Merck | 4 | $153 |
| Novartis | 4 | $151 |
| Nestle Healthcare Nutrition Inc. | 1 | $86 |
| Astellas Pharma US Inc | 1 | $77 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Philips North America LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,834 in reported general payments places this provider in the 95th percentile of 583 internal medicine providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 30 | $211 |
| Allopurinol | 13 | $98 |
| Amlodipine Besylate | 16 | $91 |
| Simvastatin | 13 | $70 |
| Metformin Hcl | 12 | $51 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Council Bluffs
- Alan KricsfeldCouncil Bluffs$49K
- Matthew FryzekCouncil Bluffs$28K
- Diana Rabadi MararCouncil Bluffs$25K
- Isam MararCouncil Bluffs$23K
- Vikrant SalariaCouncil Bluffs$7K
- Mark JohnsonMason City$223K
- Mark CarlsonSioux City$174K
- Madalyn WalshIowa City$80K
- Aziz HammoudIowa City$29K
- Ali SaeedCedar Rapids$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.